Skip to content

Author

S. Ansell

We have 3 of 91 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Perinatal and Early-Life Exposures and Risk of Non-Hodgkin Lymphoma

Greater weight at birth, in childhood, and in late adolescence were all associated with greater risk of NHL, and overall associations did not substantively vary by major NHL subtype.

G. Cholack, G. Kleinstern, Dennis P. Robinson et al. · 0 citations
Review Open access Jul 2026

Safety, feasibility, and efficacy of anti-PD-1 therapy for the treatment of classical Hodgkin lymphoma.

The clinical paradigm for treatment of classical Hodgkin lymphoma has been transformed by the use of anti-PD-1 therapy, driven by foundational work revealing near-universal 9p24.1 alterations resulting in overexpression of PD-L1 and PD-L2 on Reed-Sternberg cells. Use of PD-1 inhibitors has demonstrated remarkable clini...

J. Day, Stephen M. Ansell · 0 citations
Review

Safety, feasibility

This review seeks to examine the safety, efficacy, and feasibility of anti-PD-1 therapy in classical Hodgkin lymphoma.

J. Day, S. Ansell, Takeda Regeneron AstraZeneca Pfizer Affimed StepPharma Bristol Myers Squibb et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.